|Bid||5.11 x 1000|
|Ask||5.81 x 1300|
|Day's Range||5.14 - 5.55|
|52 Week Range||5.01 - 15.60|
|Beta (5Y Monthly)||1.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the publication of its Improving Outcomes and Antibiotic Stewardship (IOAS) Study in the journal Clinical Infectious Diseases. The multi-center, real-world study compared data before and after implementation of the Accelerate Pheno system across several hospitals to determine its impact on the treatment of patients with bloodstream infections. The data showed statistically significant reductions in time to optimal antimicrobial therapy,
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 57.14% and -11.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the third quarter for the period ended September 30, 2021, which remain subject to quarter end closing adjustments.